Report Content
Chapter 1 Methodology & Scope
1.1 Industry coverage
1.2 Market scope & definition
1.3 Base estimates & calculations
1.3.1 Data collection
1.4 Forecast parameters
1.5 COVID-19 impact analysis at global level
1.6 Data validation
1.7 Data Sources
1.7.1 Primary
1.7.2 Secondary
1.7.2.1 Paid sources
1.7.2.2 Unpaid sources
Chapter 2 Executive Summary
2.1 Cardiac marker testing industry 360º synopsis, 2018 – 2032
2.2 Business trends
2.3 Regional trends
2.4 Product trends
2.5 Biomarker type trends
2.6 Application trends
2.7 Distribution channel trends
2.8 End-use trends
Chapter 3 Cardiac Marker Testing Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Growing prevalence of cardiovascular diseases
3.2.1.2 Technological advancements
3.2.1.3 Increasing funding from public and private organizations for R&D
3.2.1.4 Rising demand for point-of-care (POC) testing
3.2.1.5 Increasing government initiatives for the diagnosis of cardiac diseases
3.2.2 Industry pitfalls & challenges
3.2.2.1 Stringent regulatory frameworks
3.2.2.2 Lack of skilled professionals
3.2.2.3 Availability of substitute product
3.3 Growth potential analysis
3.3.1 By product
3.3.2 By biomarker type
3.3.3 By application
3.3.4 By distribution channel
3.3.5 By end use
3.4 COVID- 19 impact analysis
3.5 Pricing analysis, 2022
3.6 Regulatory landscape
3.6.1 U.S.
3.6.2 Europe
3.7 Technology landscape
3.8 Future market trends
3.9 Gap analysis
3.10 Porter's analysis
3.11 PESTEL analysis
Chapter 4 Competitive Landscape, 2022
4.1 Introduction
4.2 Company matrix analysis, 2022
4.3 Company market share analysis, 2022
4.4 Competitive positioning matrix
4.5 Vendor matrix analysis
4.6 Strategy dashboard
Chapter 5 Cardiac Marker Testing Market Size and Forecast, By Product (USD Million & Units)
5.1 Key trends, by product
5.2 Consumables
5.3 Analyzers
Chapter 6 Cardiac Marker Testing Market Size and Forecast, By Biomarker Type (USD Million)
6.1 Key trends, by biomarker type
6.2 Troponins
6.3 Myoglobin
6.4 Creatine kinase (CK-MB)
6.5 Brain natriuretic peptide (BNP)
6.6 Ischemia modified albumin (IMA)
6.7 Others
Chapter 7 Cardiac Marker Testing Market Size and Forecast, By Application (USD Million)
7.1 Key trends, by application
7.2 Myocardial infarction
7.3 Congestive heart failure
7.4 Acute coronary syndrome
7.5 Atherosclerosis
7.6 Others
Chapter 8 Cardiac Marker Testing Market Size and Forecast, By Distribution Channel (USD Million)
8.1 Key trends, by distribution channel
8.2 Hospital pharmacies
8.3 Brick & mortar
8.4 E-commerce
Chapter 9 Cardiac Marker Testing Market Size and Forecast, By End-use (USD Million)
9.1 Key trends, by end-use
9.2 Hospitals
9.3 Diagnostic centers
9.4 Others
Chapter 10 Cardiac Marker Testing Market Size and Forecast, By Region (USD Million)
10.1 Key trends, by region
10.2 North America
10.2.1 U.S.
10.2.2 Canada
10.3 Europe
10.3.1 Germany
10.3.2 UK
10.3.3 France
10.3.4 Spain
10.3.5 Italy
10.3.6 Poland
10.3.7 Sweden
10.3.8 The Netherlands
10.4 Asia Pacific
10.4.1 Japan
10.4.2 China
10.4.3 India
10.4.4 Australia
10.4.5 South Korea
10.4.6 Thailand
10.4.7 Indonesia
10.4.8 Philippines
10.5 Latin America
10.5.1 Brazil
10.5.2 Mexico
10.5.3 Argentina
10.5.4 Columbia
10.5.5 Chile
10.5.6 Peru
10.6 MEA
10.6.1 South Africa
10.6.2 Saudi Arabia
10.6.3 UAE
10.6.4 Israel
10.6.5 Turkey
10.6.6 Iran
Chapter 11 Company Profiles
11.1 Abbott
11.2 Becton, Dickinson and Company
11.3 Biomérieux SA
11.4 Bio-Rad Laboratories, Inc.
11.5 Creative Diagnostics
11.6 Danaher Corporation
11.7 F. Hoffmann-La Roche Ltd.
11.8 Life Diagnostics
11.9 Perkin Elmer Inc.
11.10 Quidel Corporation
11.11 Randox Laboratories Ltd.
11.12 Siemens Healthineers
11.13 Thermo Fisher Scientific
